

23-25. June 2016

**Dear EASL/ISPOR member,
Dear Colleague,**

CHAIR

Gabor Horvath, MD
Budapest, Hungary

CO-CHAIR

Prof. Zoltan Kalo
Budapest, Hungary

CO-CHAIR

Prof. Bela Hunyady, MD
Kaposvár, Pécs Hungary

CO-CHAIR

Michael Makara, MD
Budapest, Hungary

CO-CHAIR

Prof. Markus
Peck-Radosavljevic, MD
Vienna, Austria

CO-CHAIR

Prof. Cihan Yurdaydin, MD
Ankara, Turkey

FACULTY

Prof. Rafael Esteban, MD
Barcelona, Spain

FACULTY

Prof. Graham Foster, MD
London, UK

FACULTY

Prof. Christoph Sarrazin, MD
Frankfurt, Germany

FACULTY

Dr. Csaba Dózsa, PhD, MSc
associate professor
Budapest, Hungary

Let me kindly draw your attention to the **Cost-Effectiveness (C-E) in Liver Disorders (CELD) Conference** in June this year at **Hilton Budapest**.

This is a joint EASL and ISPOR endorsed conference that will bring together medical experts, policy makers, representatives from public health science and global funders. The pharmaceutical industry and the media will also attend. The conclusions/statements from the congress will be published.

Main Topics:

C-E issues in liver cirrhosis

- Treatment choices of esophageal varices
- Diagnostic algorithm of liver nodules
- Somatostatin versus terlipressin in acute variceal bleeding
- Medical, surgical therapy, TIPs versus on-demand tap in refractory ascites
- Screening versus non-screening for HCC in non-viral cirrhosis

C-E issues in HCV

- IFN-based/IFN-free treatment versus observation in HCV with F 1-2 fibrosis
- IFN-based/IFN-free treatment versus observation in HCV with F 3-4 fibrosis
- IFN-based/IFN-free treatment versus observation in HCV prior, during and post liver transplant
- Surveillance versus no surveillance in HCV cirrhosis regressed to F2/F3 from F4 after SVR.
- Birth-cohort screening for HCV in Europe
- HCV screening at intravenous drug users and/or in HIV co-infected population





C-E issues in HBV

- Vaccination against HBV at birth versus at age 12
- Vaccination against HBV for older people
- Screening for HCC in non- cirrhotic CHB during nucleoside analogue treatment
- Entecavir versus tenofovir in decompensated HBV cirrhosis
- Screening for HCC in decompensated or compensated HBV cirrhosis

Free poster sessions

Industry sponsored symposia

WHY NOT TO MISS THE CONFERENCE?

If you are a hepatologist

- Learn about methodology of health technology assessment
- Get answers about the special cost-effectiveness issues in HCV and HBV infections

If you are a HTA specialist or payer

- Learn about the key current issues of hepatology
- Get and change ideas about financing hepatitis-C cure and hepatitis-B management

Register online with early bird discount and/or apply for young professional registration/accommodation support by 10 April 2016 and/or submit an abstract by 10 May 2016 at:

<http://www.celdbudapest.eu/online-registration/>

Should you wish further information please do not hesitate to get in touch with the conference organisers:

celd@hepatologia.hu, info@celdbudapest.eu or phone: +36 (30) 275 1181.

Kind regards,

Monika Villert
Event Organiser
Medicongress Hungary Ltd.

